Global /China /Healthcare /Medical Devices /002022
chevron_leftBack
Shanghai Kehua Bio-Engineering Co.,Ltd logo

Shanghai Kehua Bio-Engineering Co.,Ltd

002022
SHE: 002022 Delayed
5.97CNY 0.7%
0.8822 USD
As of 17 June 2026, Shanghai Kehua Bio-Engineering Co.,Ltd has a market cap of $438.44M USD, ranking #16078 globally and #5050 in China. It ranks #1445 in the Healthcare sector, and #304 in the Medical Devices industry.
Global Rank
16078
Country Rank
5050
Sector Rank
1445
Industry Rank
304
Key Stats
Market Cap
$438.44MUSD
2.97B CNY
Enterprise Value
$443.22MUSD
3.0B CNY
Revenue (TTM)
$242.56MUSD
1.64B CNY
EBITDA (TTM)
-$71.73MUSD
-485.45M CNY
Net Income (TTM)
-$108.12MUSD
-732.14M CNY
EBITDA Margin
-30%
Profit Margin
-45%
PS Ratio
1.8
PB Ratio
1.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Ming Li open_in_new
Employees
2,033
Founded
1981
Website
skhb.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.7% 4.9% 1.4% -8% -8.9% 6.2%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
002022
上海科华生物工程股份有限公司 Class A
ISIN: CNE000001KC9
Shares Out.:
500.654M1 Shares Float: 407.307M2
TV:
SA:
YF:
GF:
BA:
MS:
5.97 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Kehua Bio-Engineering Co.,Ltd

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.

Similar Companies

Industry: Medical Devices (China)
Name
Market Cap diff.
PE
$30.08B
203.66B CNY
7K%
26.0
$13.62B
92.23B CNY
3K%
48.5
$5.61B
38.02B CNY
1K%
23.4
$5.53B
37.43B CNY
1K%
52.7
688617
$5.04B
34.14B CNY
1K%
39.6
$4.56B
30.86B CNY
940%
13.7
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
39K%
25.8
$160.73B
37K%
56.7
$159.07B
36K%
25.6
DHR
$126.55B
29K%
34.7
SYK
$120.69B
27K%
38.3
MDT
$101.9B
23K%
22.2
chevron_leftBack